Analysis of Carbamazepine, Oxcarbazepine, Their Impurities, and Non-Labeled Interfering Substances by Stability-indicating UPLC/MS/MS Method: Studying the Method’s Greenness Profile
- 31 Downloads
Carbamazepine (CBZ) and oxcarbazepine (OX) are highly effective anti-psychotic drugs. In USP, it is stated that CBZ has several impurities including, iminodibenzyl (IDB), iminostilbene (IMS), and 9-methylacridine (MA). While, for OX, it is reported to have impurities like, CBZ, IMS and 9-methylacridine (MA). Presence of such impurities in various forms may reduce the efficacy and increase the side effects. It is declared that CBZ (Tegretol®) and OX (Trileptal®) oral suspensions contain methylparaben, propylparaben, and sorbic acid as preservatives. For the first time, CBZ and OX were determined with their impurities and formulation excipients with a highly selective and sensitive ecofriendly LC/MS/MS method using methanol: water containing 0.1% formic acid (95:5, v/v) as a mobile phase. Mass spectrometric quantitation was carried out in positive and negative ion modes. Application of the proposed method to quantify CBZ and OX in their tablets and oral suspensions was successfully done. The results obtained by the suggested method and the reported methods for both drugs agreed well with each other. The developed method has the advantage of being ecofriendly using the simple green mobile phase. Unlike other published methods, it is successfully applied to quantify the impurities and excipients along with parent drugs within limits recommended by USP guidelines.
KeywordsLC/MS/MS Carbamazepine Oxcarbazepine Impurities Formulation excipients Greenness profile
Both Dr. MMA and Dr. NSA did the practical work and wrote the manuscript.
Compliance with ethical standards
Conflict of interest
Authors A declares that she has no conflict of interest. Authors B declares that she has no conflict of interest.
Research involving human participants and/or animals
No human volunteers or animals were used in this work.
- 2.”The British Pharmacopoeia” (2007) Her Majesty’s. The Stationary Office, LondonGoogle Scholar
- 3.”The United States Pharmacopeia” (2012) National Formulary 35, United States Pharmacopeia Convention Inc., 30th EdGoogle Scholar
- 12.Tatar US (2006) Determination of carbamazepine in pharmaceutical preparations using high-performance liquid chromatography and derivative spectrophotometry. Turkish J Pharm Sci 3:123–139Google Scholar
- 13.Patel RB, Patel MR, Bhatt KK, Patel BG (2011) Development and validation of HPTLC method for estimation of carbamazepine in its formulations and in vitro release study. Chromatogr Res Int 2011:1–8Google Scholar
- 14.Aydoğmuş Z, Yılmaz EM, Aslan SS, Taş ZE, Üner M (2016) RP-HPLC method for the simultaneous determination of carbamazepine and nilotinib: application to solubility studies. Pharm Chem J 3:1–10Google Scholar
- 17.Kumar A, Gupta A, Kumar P, Agarwal AK (2016) Method for optimizing HPLC for separating carbamazepine and its impurities. Int J Res App Nat Soc Sci (IMPACT: IJRANS) 4:63–68Google Scholar
- 19.Reddy KS, Naidu NVS (2015) Development and validation of HPLC method for determination of oxcarbazepine in bulk and pharmaceutical formulation. Anal Chem Indian J 15:243–250Google Scholar
- 20.Bhaumik U et al. (2010) Stability-indicating HPLC method for the determination of oxcarbazepine in pharmaceutical formulation drug and pharmaceutical formulations. Asian J Chem 22:2051–2057Google Scholar
- 24.Dwivedi P, Yadav S, Rao J (2016) Validated RP HPLC method for the determination of related substance of oxcarbazepine an antiepileptic drugs. Int J PharmTech Res 9:444–451Google Scholar
- 25.Through web site: https://www.indiamart.com/frolic-pharmachem/oxcarbazepine-impurities.html. Access 23/9/2017, 21:00 PM
- 28.Kimiskidis V et al. (2007) Development and validation of a high performance liquid chromatographic method for the determination of oxcarbazepine and its main metabolites in human plasma and cerebrospinal fluid and its application to pharmacokinetic study. J Pharm Biomed Anal 43:763–768CrossRefGoogle Scholar
- 30.Kashif UH, Kumar N (2014) Development and validation of LC/MS/MS method for the simultaneous quantitative analysis of oxcarbazepine and its metabolite 10-hydroxycarbazepine in K2EDTA plasma. Int J Pharm Pharm Sci 6:422–429Google Scholar
- 31.Greiner-Sosanko E, Giannoutsos S, Lower DR, Virji MA, Krasowski MD (2007) Drug monitoring simultaneous analysis of lamotrigine, oxcarbazepine, 10- hydroxycarbazepine and zonisamide by HPLC-UV and a rapid GC method using a nitrogen-phosphorus detector for levetiracetum. J Chromatogr Sci 45:616–622CrossRefGoogle Scholar
- 32.Kundu S, Gyadangi B (2013) A simple, validated, single HPLC method for the determination of assay, dissolution, related substance of an antiepileptic drug in different pharmaceutical dosage form. Indo Am J Pharm Res 3:1722–1732Google Scholar
- 35.Raghavi K, Sindhura M, Prashanthi R, Nalluri BN (2012) Studies on forced degradation of oxcarbazepine using LC-MS compatible stability indicating RP-HPLC method. J Chem Pharm Res 4:3885–3893Google Scholar
- 36.Bhoite DS, Dhole SN, Bhoir S, Sangole P, Thorat S (2013) Development and validation of stability indicating HPTLC method for determination of oxcarbazepine in bulk and pharmaceutical formulation. Int J Pharm Pharm Sci 5:127–132Google Scholar
- 37.Fortuna A, Sousa J, Alves G, Falcão A, Soares-da-Silva P (2010) Development and validation of an HPLC-UV method for the simultaneous quantification of carbamazepine, oxcarbazepine, eslicarbazepine acetate and their main metabolites in human plasma. Anal Bioanal Chem 397:1605–1615CrossRefGoogle Scholar
- 40.Breton H, Cociglio M, Bressolle F, Peyriere H, Blayac JP, Hillaire-Buys D, Liquid chromatography-electrospray mass spectrometry determination of carbamazepine, oxcarbazepine and eight of their metabolites in human plasma. J Chromatogr B Anal Technol Biomed Life Sci 828: 80–90Google Scholar
- 45.Rowe RC, Sheskey PJ, Owen SC (2006) Handbook of pharmaceutical excipients. 5th ed., Pharmaceutical Press and American Pharmacists AssociationGoogle Scholar
- 47.Emergency Planning and Community Right-to-Know Act (2004) Section 313; Toxic Release Inventory (TRI)Google Scholar